VistaGen Therapeutics Q1 EPS $(0.94) Up From $(3.00) YoY, Sales $117.00K Down From $310.10K YoY
Portfolio Pulse from Benzinga Newsdesk
VistaGen Therapeutics reported Q1 losses of $(0.94) per share, a 68.67% increase from $(3.00) per share YoY. Sales were $117.00K, a 62.27% decrease from $310.10K YoY.
August 10, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VistaGen Therapeutics reported a decrease in sales and a smaller loss per share YoY in Q1.
While VistaGen Therapeutics reported a smaller loss per share, indicating improved profitability, the significant decrease in sales could be a concern for investors. The net impact on the stock price is uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100